NCT03795909View on ClinicalTrials.gov

Ruxolitinib Combined With Dexamethasone for HLH

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2022

Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
DRUG

Ruxolitinib

Ruxolitinib （2.5 mg twice daily for patients if the age\<14 years and the weight \<25kg，5 mg twice daily for patients if the age\<14 years and the weight≥25kg, 10mg twice daily for patients if the age ≥14 years and\<18 years）

DRUG

Dexamethasone

Dexamethasone (10mg/m2.d) delayes for the first 2 weeks（form week 1 to 2),(5mg/m2.d) from week 3 to 4，(2.5mg/m2.d) from week 5 to 6），1.25mg/m2.d for week 7，and dropped off on week 8.

Trial Locations (2)

100020

RECRUITING

Yan Yue, Beijing

Unknown

RECRUITING

Yan Yue, Beijing

Sponsors
All Listed Sponsors
lead

Capital Research Institute of Pediatrics

OTHER_GOV